Serum beta-glucuronidase in subtypes of leprosy

Area of Science:

• Biochemistry
• Immunology
• Clinical Medicine

Background:

• Leprosy is a chronic infectious disease caused by Mycobacterium leprae.
• Beta-glucuronidase is an enzyme found in various tissues, including leukocytes and liver cells.
• Elevated enzyme activity can indicate cellular damage or inflammation.

Purpose of the Study:

• To investigate serum beta-glucuronidase activity in leprosy patients.
• To compare enzyme levels across different leprosy types and treatment statuses.
• To explore the correlation between enzyme activity and disease severity or treatment.

Main Methods:

• Serum samples were collected from 176 individuals, including leprosy patients (lepromatous, borderline leprosy, borderline tuberculoid) and healthy controls.
• Phenolphthalein mono-beta-glucuronic acid was used as the substrate to measure beta-glucuronidase activity.
• Enzyme levels were analyzed in both untreated patients and those receiving multidrug therapy (dapsone and rifampicin).

Main Results:

• Serum beta-glucuronidase activity was significantly increased in all leprosy types compared to healthy controls.
• Treated lepromatous leprosy patients exhibited the highest enzyme levels (mean 105.0 SU).
• Significant differences in enzyme activity were observed between untreated patients and those on combined dapsone and rifampicin therapy across all leprosy types.

Conclusions:

• Leprosy is associated with elevated serum beta-glucuronidase activity, indicating cellular damage.
• Multidrug therapy, especially combined dapsone and rifampicin, may influence enzyme levels.
• The findings suggest extensive damage to leukocytes and liver cells in leprosy patients, particularly those on treatment.